Papayannidis, C., Schnetzke, U., Fleischmann, M., Burguera, A. D. L. F., Metzeler, K., Lane, M., Zhou, L., Hamdy, A., Cerchione, C. (2025). Preliminary pharmacokinetic and MRD results from AML patients treated with 7- and 14-day dosing schedule of emavusertib added to combination therapy with azacitidine and venetoclax. Blood. https://doi.org/10.1182/blood-2025-5201